Dr. Michael R. Hamrell, RAC, FRAPS is the President of MORIAH Consultants, a Regulatory Affairs and Clinical Research consulting firm located near Los Angeles, CA. Dr. Hamrell has a unique background with over 30 years experience in regulatory affairs, clinical research and drug development with academia, the FDA, NIH and in industry. He also worked for over 5 years at the FDA and 3 years at the NIH in the Division of AIDS, coordinating the development of drugs, biologics and vaccine products for AIDS, oncology and anti-infectives. Dr. Hamrell has dealt with Regulatory Authorities in over 40 countries and supervised all aspects of product development and approval.
Dr. Hamrell spent a number of years doing basic research, first
as a Research Fellow at Duke University and later as an Assistant
Professor of Pharmacology at the McGill University Cancer Center.
He has a Ph.D. degree in Pharmacology from the University of Southern
California and a B.S. in Biochemistry from the University of California,
Dr. Hamrell holds an appointment as Adjunct Professor of Molecular Pharmacology and Toxicology at the University of Southern California School of Pharmacy, as Adjunct Associate Professor at the Massachusetts College of Pharmacy & Health Sciences, as an Instructor at the University of North Carolina Wilmington, School of Nursing and as Adjunct Assistant Professor at the George Washington University School of Medicine Clinical Research Program and Laureate University.
Dr. Hamrell has received numerous awards for his research, teaching and professional work and is recognized in Who's Who. He has published numerous papers in pharmacology, regulatory affairs, product development, clinical research, computers and information systems.
Dr. Hamrell has served on the Editorial Board of Regulatory
Affairs FOCUS and Applied Clinical Trials.
He currently serves on the Editorial Board of Clinical
Trials Advisor, Applied Clinical Trials and Clinical Trials Magnifier and is the past Editor-in-Chief of the Drug Information Journal
and former Editor-in-Chief of the DIA Forum.